Success Metrics

Clinical Success Rate

79.4%

Based on 1,953 completed trials

Completion Rate

79%(1953/2459)

Active Trials

366(12%)

Results Posted

64%(1244 trials)

Terminated

506(16%)

Phase Distribution

Ph early_phase_1

Ph not_applicable

252

Ph phase_3

148

Ph phase_1

996

32%

Ph phase_2

1,205

38%

Ph phase_4

Phase Distribution

1054

Early Stage

1205

Mid Stage

151

Late Stage

Phase Distribution2662 total trials

Early Phase 1First-in-human

58(2.2%)

Phase 1Safety & dosage

996(37.4%)

Phase 2Efficacy & side effects

1,205(45.3%)

Phase 3Large-scale testing

148(5.6%)

Phase 4Post-market surveillance

3(0.1%)

N/ANon-phased studies

252(9.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

74.2%

1953 of 2633 finished

Non-Completion Rate

25.8%

680 ended early

Currently Active

366

trials recruiting

Total Trials

3,143

all time

Status Distribution

Active(370)

Completed(1953)

Terminated(680)

Other(140)

Detailed Status

Completed1953

Terminated506

Active, not recruiting314

Withdrawn174

unknown129

Recruiting52

Development Timeline

Analytics

Development Status

Total Trials

3143

Active

366

Success Rate

79.4%

Most Advanced

Phase 4

Trials by Phase

Early Phase 158 (2.2%)

Phase 1996 (37.4%)

Phase 21205 (45.3%)

Phase 3148 (5.6%)

Phase 43 (0.1%)

N/A252 (9.5%)

Trials by Status

terminated50616%

completed195362%

recruiting522%

suspended110%

unknown1294%

withdrawn1746%

enrolling_by_invitation20%

not_yet_recruiting20%

active_not_recruiting31410%

Recent Activity

366 active trials

Showing 5 of 3,143

recruitingphase_2

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

NCT02479698

active_not_recruitingphase_2

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT01880567

active_not_recruitingphase_1

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer

NCT03300817

active_not_recruitingphase_1

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

NCT02208375

active_not_recruitingphase_2

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

NCT02286687

View all 3,143 trials

Clinical Trials (3,143)

Showing 20 of 3,143 trialsScroll for more

NCT02479698Phase 2

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

Recruiting

NCT01880567Phase 2

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

Active Not Recruiting

NCT03300817Phase 1

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer

Active Not Recruiting

NCT02208375Phase 1

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Active Not Recruiting

NCT02286687Phase 2

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

Active Not Recruiting

NCT02232516Phase 2

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

Completed

NCT02243605Phase 2

Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

Active Not Recruiting

NCT02910700Phase 2

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Active Not Recruiting

NCT02726997Phase 1

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

Active Not Recruiting

NCT02152982Phase 2

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Active Not Recruiting

NCT00412594Phase 2

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

Recruiting

NCT02503722Phase 1

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

Active Not Recruiting

NCT00644228Phase 3

Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

Active Not Recruiting

NCT03317392Phase 1

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

Active Not Recruiting

NCT02048813Phase 3

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Active Not Recruiting

NCT01272037Phase 3

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Active Not Recruiting

NCT00602641Phase 3

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Active Not Recruiting

NCT02079662Not Applicable

The Role of Lifestyle Factors in Breast Cancer-Related Outcomes

Active Not Recruiting

NCT00310180Phase 3

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Active Not Recruiting

NCT02697227Not Applicable

Behavioral Activation Therapy and Nicotine Replacement Therapy in Increasing Smoking Cessation

Active Not Recruiting

Drug Details

Intervention Type: OTHER
Total Trials: 3,143